Overcoming CMC challenges in TIL therapy: GRIT’s strategic approach

GRIT Biotechnology is advancing tumor-infiltrating lymphocyte (TIL) therapy as a potent treatment for solid tumors. Watch this webinar for real-world insights into GRIT's approach to advancing TIL therapy development, along with a framework for evaluating novel solid tumor cell therapies based on clinical readiness, manufacturability, and scalability.

Learn more about TIL therapy workflow solutions cytiva.link/TIL